Table 6. Lipid profile at each visit.
| Baseline |
4 weeks |
8 weeks |
12 weeks (after washout period) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEAN | SEM | pa | MEAN | SEM | pa | MEAN | SEM | pa | MEAN | SEM | pa | ||
| TC (mg/dl) | |||||||||||||
| Placebo group | 218.3 | 4.4 | 0.330 | 223.0 | 4.0 | 0.103 | 228.4 b | 4.3 | 0.023 | 222.8 | 4.2 | 0.218 | |
| LcS group | 212.4 | 4.1 | 213.6 | 4.0 | 215.0 | 3.9 | 215.7 | 3.8 | |||||
| HDL-C (mg/dl) | |||||||||||||
| Placebo group | 50.8 | 1.3 | 0.255 | 52.3 | 1.6 | 0.680 | 52.6 c | 1.5 | 0.305 | 53.9 d | 1.6 | 0.745 | |
| LcS group | 53.1 | 1.5 | 53.2 | 1.5 | 55.0 | 1.8 | 54.7 | 1.7 | |||||
| LDL-C (mg/dl) | |||||||||||||
| Placebo group | 142.6 | 4.0 | 0.234 | 147.3 | 3.9 | 0.101 | 151.7 e | 4.1 | 0.022 | 147.6 | 4.0 | 0.083 | |
| LcS group | 136.1 | 3.6 | 138.2 | 3.8 | 139.2 | 3.3 | 137.9 | 3.8 | |||||
| Non-HDL-C (mg/dl) | |||||||||||||
| Placebo group | 167.6 | 4.4 | 0.173 | 170.7 | 4.3 | 0.087 | 175.8 f | 4.5 | 0.008 | 168.8 | 4.6 | 0.201 | |
| LcS group | 159.3 | 4.1 | 160.4 | 4.1 | 160.0 | 3.7 | 161.0 | 3.9 | |||||
| TAG (mg/dl) | |||||||||||||
| Placebo group | 160.3 | 9.9 | 0.614 | 159.4 | 11.3 | 0.577 | 172.5 | 12.9 | 0.120 | 144.3 | 10.0 | 0.275 | |
| LcS group | 153.4 | 9.4 | 151.1 | 9.3 | 147.0 | 9.8 | 179.8 | 31.2 | |||||
LcS: L. casei strain Shirota YIT 9029; TC: total cholesterol; LCL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; TAG: triacylglycerol.
ap values analysed by the unpaired Student’s t-test.
b–fMean values were significantly different from those at baseline (paired Student’s t-test with Bonferroni-Holm adjustment). The p values were as follows: bp=0.001; cp=0.042; dp=0.016; ep=0.000; fp=0.004.